Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Journal:
Nature Medicine
Published:
Affiliations:
29
Authors:
28
Institutions Authors Share
Erasmus MC Cancer Institute, Netherlands
2.500000
0.09
University of Turin (UNITO), Italy
1.500000
0.05
A.O.U. Citta della Salute e della Scienza di Torino, Italy
1.500000
0.05
Korea University, South Korea
1.500000
0.05
University Medical Center Groningen (UMCG), RUG, Netherlands
1.000000
0.04
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain
1.000000
0.04
Amphia Hospital, Netherlands
1.000000
0.04
IJC-IGTP-ICO, Spain
1.000000
0.04
Theageneio Hospital of Thessaloniki, Greece
1.000000
0.04
Ziekenhuis aan de Stroom (ZAS), Belgium
1.000000
0.04
Clínica Universidad de Navarra (CUN), UNAV, Spain
1.000000
0.04
Careggi University Hospital (AOUC), UNIFI, Italy
1.000000
0.04
Instituto de Investigación Hospital 12 de Octubre (i+12), Spain
1.000000
0.04
St. Antonius Hospital, Netherlands
1.000000
0.04
Cancer Center Amsterdam (CCA), Netherlands
1.000000
0.04
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany
1.000000
0.04
University Hospital Brno, Czech Republic
1.000000
0.04
University Hospital Hradec Králové, Czech Republic
1.000000
0.04
Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia, Italy
1.000000
0.04
University Hospital of Würzburg (UKW), JMU, Germany
1.000000
0.04
European Myeloma Network, Italy
1.000000
0.04
National and Kapodistrian University of Athens (UOA), Greece
0.500000
0.02
University Hospital Ostrava, OSU, Czech Republic
0.500000
0.02
University of Ostrava (OSU), Czech Republic
0.500000
0.02
Sant'Orsola Malpighi Hospital, Italy
0.500000
0.02
University of Bologna (UNIBO), Italy
0.500000
0.02
Oslo University Hospital (OUS), Norway
0.500000
0.02
University of Oslo (UiO), Norway
0.500000
0.02
European Myeloma Network (EMN) - Netherlands, Netherlands
0.500000
0.02